Immuneering Corp — Director's Dealing 2021

Aug 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2021-08-03

Reporting Person: Zeskind Benjamin J. (Director, President and CEO, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-03	Class A Common Stock	C	49099	—	Acquired	2598171	Direct
2021-08-03	Class A Common Stock	P	2098	$15.00	Acquired	2600269	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-03	Series A Preferred Stock	$	C	40928	Disposed		Class A Common Stock (40928)	Direct
2021-08-03	Series B Preferred Stock	$	C	8171	Disposed		Class A Common Stock (8171)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Class A Common Stock	544927	Indirect

Footnotes

F1: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.

F2: Held by the Benjamin J. Zeskind 2020 Family Trust, where Lisa Schwartz, Dr. Zeskind's spouse, serves as sole trustee.